Hypotheses
499 hypotheses · 178 with trials running
Showing 19 items
Stop relapses
relapsing MSConfirmedPhase 438 trials · 12 running · Divozilimab, Ocrelizumab, Ofatumumab, Rituximab and 1 more
Stop relapses
relapsing and progressive MSConfirmedPhase 410 trials · 6 running · Ocrelizumab, Ofatumumab, Rituximab
Slow progression
primary progressive MSMixedPhase 38 trials · 3 running · Ocrelizumab, Rituximab
Slow progression
relapsing MSBeing testedPhase 414 trials · 3 running · Ocrelizumab, Ofatumumab, Rituximab, Ublituximab
Slow progression
secondary progressive MSBeing testedPhase 37 trials · 5 running · Ocrelizumab, Rituximab
Stop relapses
NMOSDBeing testedPhase 45 trials · 3 running · Divozilimab, Ofatumumab, Rituximab
Protect nerves
relapsing MSBeing testedPhase 43 trials · 2 running · Ocrelizumab, Ublituximab
Stop relapses
primary progressive MSBeing testedPhase 43 trials · 1 running · Ocrelizumab
Protect nerves
relapsing and progressive MSBeing testedPhase 42 trials · 1 running · Ocrelizumab
Slow progression
relapsing and progressive MSBeing testedPhase 42 trials · 1 running · Ocrelizumab
Slow progression
MS (type not specified)Being testedPhase 32 trials · 1 running · Ocrelizumab
Stop relapses
secondary progressive MSBeing testedPhase 42 trials · 1 running · Ocrelizumab
Stop relapses
MS (type not specified)Being testedPhase 32 trials · 1 running · Rituximab
Stop relapses
MOGADBeing testedPhase 31 trial · 1 running · Rituximab
Protect nerves
secondary progressive MSNo clear answerPhase 22 trials · 0 running · Rituximab
Slow progression
NMOSDNo clear answerPhase 2/32 trials · 0 running · Rituximab, Ublituximab
Prevent or delay MS
early MS (CIS or RIS)No clear answerPhase 41 trial · 0 running · Ocrelizumab
Protect nerves
primary progressive MSNo clear answerPhase 21 trial · 0 running · Rituximab
Stop relapses
early MS (CIS or RIS)No clear answerPhase 41 trial · 0 running · Ocrelizumab
How a status is decided
A hypothesis is Confirmed when two or more controlled phase 3 trials met their main goal, or when one did and a medicine of the same approach is approved in the EU or the US for that use. With one positive phase 3 trial and no approval it is Supported by one trial. Analyses that only compare an active comparator with placebo, such as interferon beta against placebo inside a laquinimod trial, do not count as the tested medicine’s result.
- Confirmed
- Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Supported by one trial
- One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Promising
- Worked in a controlled phase 2 trial. A signal, not proof.
- Mixed
- Controlled trials disagree.
- Results pending
- Trials finished, but not all results are read yet.
- Being tested
- Trials are running now. No verdict yet.
- Failed in phase 2
- Controlled phase 2 trials did not meet their main goal for this group.
- Failed in phase 3
- Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- No clear answer
- Tried, but no controlled phase 2 or 3 result yet.
- Not yet tested
- Proposed or suggested by genetics. Not yet tested in MS.
Unread results can leave a status pending. Two or more phase 3 trials that met their goal, with none against, give a verdict even when an extension study at the same phase has no readable result.
“Failed in phase 3” applies to the patient group shown. A hypothesis can fail in primary progressive MS and work in relapsing MS.
Not yet tested items come from two places: proposed hypotheses, and genes linked to MS by human genetics that existing medicines act on but that have never been tried in MS.
Nothing here is linked or edited by hand. To report an error, use the contact form; we fix the rule, so the fix applies everywhere.